MedTrace Logo

Screening to Improve Survival in AL Amyloidosis

NCT04615572 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 35

Last updated 2024-10-28

No results posted yet for this study

Summary

The purpose of this study is to see whether certain genes may be linked with the development of AL amyloidosis in subjects 60 years of age or older with the blood disorders SMM and MGUS. A limited repertoire of immunoglobulin (Ig) variable region genes have been associated with AL amyloidosis. The clonal plasma cells of subjects with SMM and MGUS may express one of these Ig variable region genes indicating a risk of progression to AL amyloidosis and potentially enabling early diagnosis. We hope this study will help us begin to understand whether Ig variable region gene identification can be a useful tool for assessing a subject's risk of progression to AL amyloidosis.

Conditions

  • Smoldering Multiple Myeloma
  • Monoclonal Gammopathy of Undetermined Significance

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Tufts Medical Center

    lead OTHER

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-28
Primary Completion
2023-07-06
Completion
2023-07-06

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04615572 on ClinicalTrials.gov